ribosomal protein L35a pseudogene 4Genealiases: []
Q-omics provides the consensus-scored RPL35AP4 profile across patient tissues and cancer cell-line models. RPL35AP4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL35AP4 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, RPL35AP4 RNA expression shows 7,498 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, UCEC, and THYM as cancer lineages where RPL35AP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35AP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35AP4 survival associations across molecular data types. RPL35AP4 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35AP4 RNA expression–survival associations across cancer types. High RPL35AP4 expression shows unfavorable associations in ACC, MESO and LIHC, but favorable associations in CESC, BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL35AP4 RNA expression.
This table summarizes RPL35AP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL35AP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35AP4 shows higher tumor expression in UCEC, LUSC, COAD and LIHC. The UCEC box plot shows higher RPL35AP4 RNA expression in tumor versus normal tissue (log2 FC = +1.830, t-test p < 0.001).
This table shows molecular features associated with RPL35AP4 in patient tissues and cancer cell lines. In patient samples, RPL35AP4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
